Assembly Biosciences
ASMBAssembly Biosciences is a biotechnology company focused on developing innovative therapeutics for serious viral diseases, including recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV).
Earnings
Next report
Aug 5, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Assembly Biosciences is a biotechnology company focused on developing innovative therapeutics for serious viral diseases, including recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV). The company leverages its deep virology expertise to advance a pipeline of clinical-stage candidates designed to disrupt viral replication cycles and address significant unmet medical needs.
A clinical-stage innovator in virology with a strategic collaboration with a major pharmaceutical leader for late-stage development.
Questions, answered.
- What is Assembly Biosciences's market cap?
- Assembly Biosciences (ASMB) has a market capitalization of $513.5M and trades on NASDAQ.
- What is Assembly Biosciences's revenue and profitability?
- Assembly Biosciences generated $71.1M in trailing twelve-month revenue with a net loss of $37.3M, representing a net margin of -103.6%, with free cash flow of -$77.5M. These figures are based on the Q1 2026 filing.
- Who are Assembly Biosciences's competitors?
- Assembly Biosciences's key competitors include Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Enanta Pharmaceuticals, Inc, and others. These companies compete in similar markets and product categories.
- Who does Assembly Biosciences partner with?
- Assembly Biosciences's notable partners include Gilead Sciences, Inc..
- Where is Assembly Biosciences headquartered?
- Assembly Biosciences is headquartered in United States of America and employs approximately 65 people. It has been publicly traded since 2010.
